IN8Bio

About IN8Bio

IN8Bio operates as a clinical-stage biopharmaceutical firm, directing its efforts toward the discovery, development, and commercialization of gamma-delta T cell therapies for cancer treatment. The company was incorporated in 2016, with its initial public offering occurring in August 2021, which raised approximately $40 million. The scientific foundation of IN8Bio is built upon the research of co-founder Lawrence Lamb, PhD, who serves as the Chief Scientific Officer and has dedicated over two decades to the study of gamma-delta T cells. His extensive background in cellular immunology and bone marrow transplantation at the University of Alabama at Birmingham directly informs the company's therapeutic approach. William Ho, the President and CEO, brings significant experience in biotechnology investment banking and corporate development to the company's leadership.

The company's core focus is on a specific type of immune cell, the gamma-delta T cell, which possesses the natural ability to distinguish between healthy and cancerous tissues. IN8Bio's proprietary DeltEx platform encompasses its expertise in gamma-delta T cell biology, genetic engineering, and specialized manufacturing processes. Through this platform, the company develops therapies using both allogeneic (donor-derived) and autologous (patient-derived) cells, including genetically modified versions, to target and eliminate tumor cells effectively. IN8Bio's business model is centered on advancing its pipeline of drug candidates through clinical trials to gain regulatory approval and subsequently commercialize these therapies. The primary clients are patients with various forms of cancer, including solid tumors and hematologic malignancies like leukemia.

IN8Bio's therapeutic pipeline includes several candidates at different stages of clinical investigation. One of their lead programs involves genetically modifying gamma-delta T cells to be resistant to chemotherapy, allowing them to be administered concurrently with standard-of-care treatments to potentially improve patient outcomes. This positions IN8Bio as a notable entity in the gamma-delta T cell space, having advanced genetically modified versions of these cells into clinical trials. The company is conducting multiple Phase 1 and Phase 2 clinical trials for conditions such as newly diagnosed and recurrent glioblastoma and for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.